Figures & data
Table 1. Characteristics of treated elderly Medicare Beneficiaries with newly Diagnosed MCL between 1 January 2010 and 31 December 2018 by line of treatment received.
Table 2. Type of MCL treatment received by line of therapy among elderly Medicare Beneficiaries treated for MCL, 2010 to 2019.
Figure 1. Overall survival rates from initiation of each line of treatment among Medicare Beneficiaries with Diagnosed MCL.
Table 3. Healthcare resource utilization among Medicare Beneficiaries with Diagnosed MCL in the 12-months after initiation of the specific line of treatment.
Figure 2. All-Cause and MCL-related* Total healthcare costs among Medicare Beneficiaries with Diagnosed MCL in the 12-months after initiation of the specific line of treatment. Costs were inflated to 2020 US dollars using the medical care component of the 2020 U.S. Consumer Price Index.
*MCL-related costs were identified based on claims with a diagnosis of MCL in any position and/or drug codes for one of the MCL indicated drug treatments.
Figure 3. MCL-related* medical and prescription drug costs among medicare beneficiaries with diagnosed MCL in the 12-months after initiation of the specific line of treatment.
Costs were inflated to 2020 US dollars using the medical care component of the 2020 U.S. Consumer Price Index.
* MCL-related costs were identified based on claims with a diagnosis of MCL in any position and/or drug codes for one of the MCL indicated drug treatments.
